Montelukast Doc (Montelukast)

Montelukast blocks the cysteinyl leukotriene receptor CysLT1, preventing leukotrienes D4, C4, and E4 from binding. This inhibition reduces bronchoconstriction, vascular leakage, and eosinophil recruitment, leading to decreased airway inflammation and improved breathing.

The specific dose of Montelukast Doc is determined by the prescribing clinician based on the patient’s age, condition severity, and treatment goals. Dosage adjustments are individualized and should follow the prescriber’s instructions.

Montelukast is classified as Pregnancy Category B, indicating no evidence of risk in animal studies but limited human data. It is excreted in breast milk in small amounts; use only if the potential benefit justifies any possible risk to the infant.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Montelukast and inhaled corticosteroids act via different mechanisms; montelukast blocks leukotriene receptors, while corticosteroids suppress broad inflammatory pathways. Montelukast is often used as an add‑on therapy for patients who need additional control, but it does not replace inhaled steroids for persistent asthma.

Montelukast Doc should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in their original container, protect them from moisture and direct sunlight, and ensure the packaging remains tightly closed.

Montelukast Doc is taken orally, usually once daily in the evening, with or without food. The tablet should be swallowed whole with a glass of water; it should not be crushed, chewed, or split unless specifically instructed by a healthcare professional.

Serious risks include rare neuropsychiatric events such as depression, suicidal thoughts, or hallucinations, and allergic reactions that may manifest as rash, angioedema, or anaphylaxis. Patients should seek immediate medical attention if they experience any of these symptoms.

Montelukast Doc is contraindicated in individuals with known hypersensitivity to montelukast or any of its excipients. Caution is advised for patients with severe hepatic impairment, and it should not be used as a sole rescue medication for acute asthma attacks.